{"created":"2023-05-15T16:30:49.792168+00:00","id":2104,"links":{},"metadata":{"_buckets":{"deposit":"678a5358-6ebd-49d3-967f-50c560cac6cc"},"_deposit":{"created_by":2,"id":"2104","owners":[2],"pid":{"revision_id":0,"type":"depid","value":"2104"},"status":"published"},"_oai":{"id":"oai:nagasaki-u.repo.nii.ac.jp:00002104","sets":["8:9"]},"author_link":["9732","9735","9739","9740","9729","9742","9741","9738","9737","9733","9734","9730","9731","9736"],"item_2_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2016-07-03","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"4","bibliographicPageEnd":"472","bibliographicPageStart":"467","bibliographicVolumeNumber":"7","bibliographic_titles":[{"bibliographic_title":"Thoracic Cancer"}]}]},"item_2_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Background: Uridine 5′-diphospho-glucuronosyltransferase 1A1 (UGT1A1*27) is known to impair the effect of UGT in basic research; however, little clinical investigation has been conducted. To evaluate the effect of the UGT1A1*27 polymorphism in irinotecan therapy, we conducted a prospective study. Methods: Eligibility criteria included: lung cancer patients; scheduled irinotecan therapy doses of single ? 80, combination ? 50, radiation with single ? 50, or radiation with combination ? 40 mg/m2; age ? 20; and Eastern Cooperative Oncology Group performance score (PS) 0?2. Patients were examined for UGT1A1*28 and *6 polymorphisms and received irinotecan. When the UGT1A1*28 polymorphism was detected, a search for UGT1A1*27 was conducted. Fifty patients were enrolled, with 48 patients determined eligible. Results: UGT1A1 polymorphisms *28/*28, *6/*6, *28/*6, *28/?, *6/?, ?/? observed 0 (0%), 1 (2%), 1 (2%), 7 (15%), 17 (35%) and 22 (46%), respectively. UGT1A1*27 were examined in nine patients including one ineligible patient; however, no polymorphisms were found. The study ceased after interim analysis. In an evaluation of the side effects of irinotecan, patients with UGT1A1*28 and UGT1A1*6 polymorphisms had a higher tendency to experience febrile neutropenia than wild type (25% and 32% vs. 14%). Incidences of grade 3/4 leukopenia and neutropenia were significantly higher in patients with UGT1A1*28 polymorphisms compared with wild type (75% vs. 32%, P = 0.049; 75% vs. 36%, P = 0.039, respectively). Conclusion: Our prospective study did not locate the UGT1A1*27 polymorphism, suggesting that UGT1A1*27 does not significantly predict severe irinotecan toxicity in cancer patients.","subitem_description_type":"Abstract"}]},"item_2_description_63":{"attribute_name":"引用","attribute_value_mlt":[{"subitem_description":"Thoracic Cancer, 7(4), pp.467-472; 2016","subitem_description_type":"Other"}]},"item_2_publisher_33":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"John Wiley and Sons Inc."}]},"item_2_relation_12":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"10.1111/1759-7714.12360","subitem_relation_type_select":"DOI"}}]},"item_2_rights_13":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"c 2016 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd"},{"subitem_rights":"This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes."}]},"item_2_source_id_7":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"17597706","subitem_source_identifier_type":"ISSN"}]},"item_2_version_type_16":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Fukuda, Minoru"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Suetsugu, Takayuki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Shimada, Midori"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Kitazaki, Takeshi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Hashiguchi, Kohji"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Kishimoto, Junji"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Harada, Taishi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Seto, Takashi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Ebi, Noriyuki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Takayama, Koichi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Sugio, Kenji"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Semba, Hiroshi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Nakanishi, Yoichi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Ichinose, Yukito"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-12-21"}],"displaytype":"detail","filename":"ThoCan7_467.pdf","filesize":[{"value":"164.5 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"ThoCan7_467.pdf","url":"https://nagasaki-u.repo.nii.ac.jp/record/2104/files/ThoCan7_467.pdf"},"version_id":"e0cb1512-3aa9-407c-a407-7b19ee1d803a"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Gene polymorphism","subitem_subject_scheme":"Other"},{"subitem_subject":"irinotecan","subitem_subject_scheme":"Other"},{"subitem_subject":"lung cancer","subitem_subject_scheme":"Other"},{"subitem_subject":"prospective","subitem_subject_scheme":"Other"},{"subitem_subject":"UGT1A1","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Prospective study of the UGT1A1*27 gene polymorphism during irinotecan therapy in patients with lung cancer: Results of Lung Oncology Group in Kyusyu (LOGIK1004B)","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Prospective study of the UGT1A1*27 gene polymorphism during irinotecan therapy in patients with lung cancer: Results of Lung Oncology Group in Kyusyu (LOGIK1004B)"}]},"item_type_id":"2","owner":"2","path":["9"],"pubdate":{"attribute_name":"公開日","attribute_value":"2017-05-16"},"publish_date":"2017-05-16","publish_status":"0","recid":"2104","relation_version_is_last":true,"title":["Prospective study of the UGT1A1*27 gene polymorphism during irinotecan therapy in patients with lung cancer: Results of Lung Oncology Group in Kyusyu (LOGIK1004B)"],"weko_creator_id":"2","weko_shared_id":-1},"updated":"2023-05-16T03:52:38.676535+00:00"}